Posts by Mourabit Halima

At the recent Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Cai Zhen and Professor He Jingsong from The First Affiliated Hospital, Zhejiang University School of Medicine, had 12 studies accepted, comprehensively showcasing systematic investigations in multiple myeloma ranging from basic research to clinical translation. These studies focused on key scientific questions including the roots of disease relapse, mechanisms of drug resistance, prognostic evaluation, and therapeutic strategies, forming an integrated evidence chain from mechanistic discovery to clinical application. During the meeting, Hematology Frontier invited Professor Cai Zhen to provide an in-depth interpretation of the team’s research achievements and outline future research plans, offering valuable academic insights to advance the diagnosis and treatment of multiple myeloma.

The 67th Annual Meeting of the American Society of Hematology (ASH) was held from December 6 to 9, 2025, in Orlando, bringing together the latest global advances in hematology research and clinical practice. At this year’s meeting, the team led by Professor Hu Kai from Beijing Gaobo Hospital presented seven studies focusing on CAR-T cell therapy across different types of relapsed/refractory lymphoma, including B-cell lymphoma, central nervous system lymphoma, T-cell lymphoma, as well as combined strategies involving CAR-T therapy and hematopoietic stem cell transplantation. These studies provide important evidence supporting the further development of individualized treatment strategies. Oncology Frontier – Hematology Frontier invited Professor Hu Kai to provide an in-depth interpretation of these key findings and their clinical significance.

The 67th Annual Meeting of the American Society of Hematology (ASH) was held grandly in Orlando from December 6 to 9, 2025, bringing together the latest research and clinical advances…

Despite the remarkable progress achieved with single-target CAR-T therapy in the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL), a proportion of patients still experience suboptimal responses or relapse after treatment. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Wang Liang from Beijing Tongren Hospital, Capital Medical University, was selected for an oral presentation, reporting impressive results from a phase II clinical trial of dual-target CD19/CD22 CAR-T cell therapy in R/R LBCL. The findings attracted wide attention. Hematology Frontier invited Professor Wang Liang for an in-depth discussion of the innovative aspects of this study, offering valuable insights for future optimization of R/R LBCL treatment strategies and research directions.

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was grandly held in Orlando, USA. As the world’s largest and most influential international academic conference in the field of hematology, the ASH Annual Meeting attracts tens of thousands of experts and scholars each year to share the latest advances and breakthrough research. At this year’s meeting, a study led by Professor Sun Ruijuan from Lu Daopei Hospital was selected for poster presentation, focusing on the clinical efficacy of allogeneic hematopoietic stem cell transplantation in infant acute leukemia, providing important insights for the treatment of this challenging patient population. Hematology Frontier invited Professor Sun to share the details of this study for academic exchange.